Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2020

14.11.2019 | Original Article

Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population

verfasst von: Theresa H. Nguyen, Niharika Mallepally, Tariq Hammad, Yan Liu, Aaron P. Thrift, Hashem B. El-Serag, Mimi C. Tan

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Helicobacter pylori infection is an established causal factor for non-cardia gastric cancer. H. pylori negative gastric cancer prevalence among US patients is unclear.

Methods

This retrospective cohort study examined H. pylori prevalence among consecutive patients with incident non-cardia gastric adenocarcinoma at the Houston VA Hospital (11/2007–10/2018). H. pylori positivity was defined by H. pylori on histopathology, positive antibody serology, stool antigen, or urea breath testing. We examined for trends in H. pylori negative gastric cancer based on year of diagnosis. Associations between histopathologic and cancer-related outcomes with H. pylori positivity were determined using regression models.

Results

Of 91 patients with gastric adenocarcinoma, most were men (N = 87, 95.6%), black (N = 47, 51.6%), with mean age at diagnosis of 68.0 years (SD 10.8). In addition to gastric cancer biopsy histopathology, 74 patients (81.3%) had ≥ 1 testing for H. pylori, including antibody serology (n = 34), non-cancer gastric biopsy histopathology (n = 63), or stool antigen (n = 1). The overall prevalence of H. pylori infection was 38.5% and 45.9% among patients with ≥ 2 H. pylori tests. The proportions of H. pylori positive gastric cancer decreased from 50.0% (2007–2010) to 43.4% (2011–2014) and 29.3% (2015–2018) (p = 0.096). Active/acute gastritis (adjOR 3.74), atrophic gastritis (adjOR 15.30), and gastric intestinal metaplasia (adjOR 3.65) were associated with H. pylori positive gastric cancer.

Discussion

The prevalence of H. pylori infection among patients with non-cardia gastric adenocarcinoma is relatively low (38.5–45.9%) and decreasing over time. This finding suggests there may be other important causal factors apart from H. pylori for gastric adenocarcinoma.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer. Published 2013. Accessed January 2019. Ferlay J, Soerjomataram I, Ervik M. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer. Published 2013. Accessed January 2019.
2.
Zurück zum Zitat Cancer IAfRo. Estimated age-standardized incidence rates in 2018, worldwide, both sexes, all ages. In: Globocan. International Agency for Research on Cancer; 2018. Cancer IAfRo. Estimated age-standardized incidence rates in 2018, worldwide, both sexes, all ages. In: Globocan. International Agency for Research on Cancer; 2018.
3.
Zurück zum Zitat IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Gastric Cancer Prevention 2014; No. January, Lyon, France. IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Gastric Cancer Prevention 2014; No. January, Lyon, France.
4.
Zurück zum Zitat Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487–490.CrossRef Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487–490.CrossRef
5.
Zurück zum Zitat Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev. 2016;25:16–27.CrossRef Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev. 2016;25:16–27.CrossRef
6.
Zurück zum Zitat Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter. 2017;22:e12403.CrossRef Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter. 2017;22:e12403.CrossRef
7.
Zurück zum Zitat Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust. 2016;204:376–380.CrossRef Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust. 2016;204:376–380.CrossRef
8.
Zurück zum Zitat Lim SH, Kim N, Kwon JW, et al. Trends in the seroprevalence of Helicobacter pylori infection and its putative eradication rate over 18 years in Korea: a cross-sectional nationwide multicenter study. PLoS ONE. 2018;13:e0204762.CrossRef Lim SH, Kim N, Kwon JW, et al. Trends in the seroprevalence of Helicobacter pylori infection and its putative eradication rate over 18 years in Korea: a cross-sectional nationwide multicenter study. PLoS ONE. 2018;13:e0204762.CrossRef
9.
Zurück zum Zitat Eom BW, Jung KW, Won YJ, Yang H, Kim YW. Trends in gastric cancer incidence according to the clinicopathological characteristics in Korea, 1999–2014. Cancer Res Treat Off J Korean Cancer Assoc. 2018;50:1343–1350. Eom BW, Jung KW, Won YJ, Yang H, Kim YW. Trends in gastric cancer incidence according to the clinicopathological characteristics in Korea, 1999–2014. Cancer Res Treat Off J Korean Cancer Assoc. 2018;50:1343–1350.
10.
Zurück zum Zitat Anderson WF, Rabkin CS, Turner N, Fraumeni JF Jr, Rosenberg PS, Camargo MC. The changing face of noncardia gastric cancer incidence among US Non-Hispanic whites. J Natl Cancer Inst. 2018;110:608–615.CrossRef Anderson WF, Rabkin CS, Turner N, Fraumeni JF Jr, Rosenberg PS, Camargo MC. The changing face of noncardia gastric cancer incidence among US Non-Hispanic whites. J Natl Cancer Inst. 2018;110:608–615.CrossRef
11.
Zurück zum Zitat Uemera N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789.CrossRef Uemera N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789.CrossRef
12.
Zurück zum Zitat Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–419.CrossRef Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–419.CrossRef
13.
Zurück zum Zitat Ono S, Kato M, Suzuki M, et al. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic, and serological atrophy. Digestion. 2012;86:59–65.CrossRef Ono S, Kato M, Suzuki M, et al. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic, and serological atrophy. Digestion. 2012;86:59–65.CrossRef
14.
Zurück zum Zitat Kim HJ, Kim N, Yoon H, et al. Comparison between resectable Helicobacter pylori-negative and -positive gastric cancers. Gut Liver. 2016;10:212–219.CrossRef Kim HJ, Kim N, Yoon H, et al. Comparison between resectable Helicobacter pylori-negative and -positive gastric cancers. Gut Liver. 2016;10:212–219.CrossRef
15.
Zurück zum Zitat Marrelli D, Pedrazzani C, Berardi A, et al. Negative Helicobacter pylori status is associated with poor pronogosis in patients with gastric cancer. Cancer. 2009;115:2071–2080.CrossRef Marrelli D, Pedrazzani C, Berardi A, et al. Negative Helicobacter pylori status is associated with poor pronogosis in patients with gastric cancer. Cancer. 2009;115:2071–2080.CrossRef
16.
Zurück zum Zitat Meimarakis G, Winter H, Assmann I, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7:211–222.CrossRef Meimarakis G, Winter H, Assmann I, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7:211–222.CrossRef
17.
Zurück zum Zitat Hooi J, Lai W, Ng W, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420–429.CrossRef Hooi J, Lai W, Ng W, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420–429.CrossRef
18.
Zurück zum Zitat Graham D. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014;20:5191–5204.CrossRef Graham D. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014;20:5191–5204.CrossRef
20.
Zurück zum Zitat Wang Z, Graham DY, Khan A, et al. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol. 2018;47:966–975.CrossRef Wang Z, Graham DY, Khan A, et al. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol. 2018;47:966–975.CrossRef
22.
Zurück zum Zitat Palestro G, Pellicano R, Fronda GR, et al. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. World J Gastroenterol. 2005;11:7131–7135.CrossRef Palestro G, Pellicano R, Fronda GR, et al. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. World J Gastroenterol. 2005;11:7131–7135.CrossRef
23.
Zurück zum Zitat Kim JH, Cheung DY. Must-have knowledge about the Helicobacter pylori-negative gastric cancer. Gut Liver. 2016;10:157–159.CrossRef Kim JH, Cheung DY. Must-have knowledge about the Helicobacter pylori-negative gastric cancer. Gut Liver. 2016;10:157–159.CrossRef
24.
Zurück zum Zitat Shiota S, Thrift AP, Green L, et al. Clinical manifestations of Helicobacter pylori-negative gastritis. Clin Gastroenterol Hepatol. 2017;15:1037–1046.CrossRef Shiota S, Thrift AP, Green L, et al. Clinical manifestations of Helicobacter pylori-negative gastritis. Clin Gastroenterol Hepatol. 2017;15:1037–1046.CrossRef
25.
Zurück zum Zitat Nordenstedt H, Graham DY, Kramer JR, et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013;108:65–71.CrossRef Nordenstedt H, Graham DY, Kramer JR, et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013;108:65–71.CrossRef
26.
Zurück zum Zitat Yamamoto Y, Fujisaki J, Omae M, Hirasawa T, Igarashi M. Helicobacter pylori-negative gastric cancer: characteristics and endoscopic findings. Dig Endosc. 2015;27:551–561.CrossRef Yamamoto Y, Fujisaki J, Omae M, Hirasawa T, Igarashi M. Helicobacter pylori-negative gastric cancer: characteristics and endoscopic findings. Dig Endosc. 2015;27:551–561.CrossRef
Metadaten
Titel
Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population
verfasst von
Theresa H. Nguyen
Niharika Mallepally
Tariq Hammad
Yan Liu
Aaron P. Thrift
Hashem B. El-Serag
Mimi C. Tan
Publikationsdatum
14.11.2019
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2020
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05955-2

Weitere Artikel der Ausgabe 8/2020

Digestive Diseases and Sciences 8/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.